Showing results (21-30 of 38) with videos related to
Sort By:
Pageof 4
Endocrine-Related Cancer|September 2, 2016
Brachyury, a vaccine target, is overexpressed in triple-negative breast cancerDuane H Hamilton, Mario Roselli, Patrizia Ferroni, et al.Journal for Immunotherapy of Cancer|September 7, 2023
Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysisMadeline Dahut, Kristen Fousek, Lucas A Horn, et al.Journal for Immunotherapy of Cancer|July 8, 2024
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccinesJeffrey Schlom, Renee N Donahue, Claudia Palena, et al.Cancer Research|February 13, 2014
Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic processAndressa Ardiani, Sofia R Gameiro, Claudia Palena, et al.Cancers|March 6, 2021
Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination ImmunotherapyLucas A Horn, Kristen Fousek, Duane H Hamilton, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2022
An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLCKristen Fousek, Lucas A Horn, Haiyan Qin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2016
Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung CancerDuane H Hamilton, Lesley Mathews Griner, Jonathan M Keller, et al.Oncotarget|October 16, 2013
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccineDuane H Hamilton, Mary T Litzinger, Alessandra Jales, et al.Journal for Immunotherapy of Cancer|May 13, 2025
Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor controlMaria Del Mar Maldonado, Maria Gracia-Hernandez, Loc Huu Le, et al.Cell Reports|October 12, 2017
Brachyury-YAP Regulatory Axis Drives Stemness and Growth in CancerSagar R Shah, Justin M David, Nathaniel D Tippens, et al.Pageof 4